Regenerative medicine company Mesoblast limited
(ASX:MSB) has received $5.8 million from the Australian government’s R&D tax incentive program.
The US-Australian company says the grant helped to cover research and development activities in the 2014 financial year.
Mesoblast says it anticipates it will continue to receive government funding in the future regarding the development of next generation cell-based products.
Mesoblast reported a net loss of $50 million in the first half of the 2015 financial year.
